UK markets close in 7 hours 45 minutes

BioSenic S.A. (0R55.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.0234-0.0015 (-6.02%)
As of 02:54PM BST. Market open.
Full screen
Previous close0.0249
Open0.0000
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.0000 - 0.0000
52-week range
Volume15,000
Avg. volume12,067
Market cap2,391
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.7670
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    BioSenic provides further information on its restructuring plan

    PRESS RELEASE - PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, 12 April 2024, 12:00 CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, as part of the global restructuring plan announced on 11 April 2024, provides information on (i) the Company's current debt position and the potential impact of the plan on this position and (ii) links to the Company's website to consult the conversion

  • GlobeNewswire

    BioSenic and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of Nivelles

    PRESS RELEASE - PRIVILEGED INFORMATION A final circular of the creditors on the basis of XX 83/23 of the Economic Law Code (ELC) will take place before the Court grants authorisation, in accordance with article XX 83/26 of the ELC, to submit the plan to the vote of each class of creditors and to homologation. The creditors will be aware of the plan, which by law contains information that could be privileged. Mont-Saint-Guibert, Belgium, 11 April 2024, 14:00 CET – BioSenic (Euronext Brussels and

  • GlobeNewswire

    BioSenic S.A. : Information on the total number of voting rights and shares

    PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, March 29, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published in accordance with Article 15 of the Belgian law of 2 May 2007 on the publication of major s